InMode (INMDN) AI Stock Analysis

InMode

(BMV:INMDN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Very low leverageAn exceptionally conservative capital structure gives InMode resilience if demand weakens and preserves capacity to fund product development, commercial investment, or shareholder returns. Minimal debt also limits refinancing exposure and interest burdens, supporting durable financial flexibility over the coming quarters.

Negative Factors

Weak revenue trajectoryA flat revenue base following two years of declines indicates that demand and commercial momentum have cooled from earlier periods. Sustained stagnation could constrain operating leverage, limit reinvestment capacity, and make future earnings growth more dependent on cost control.

InMode (INMDN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 760.73M
Dividend Yield: ―
Average Volume (3M): 5,507
Price to Earnings (P/E): 10.6
Beta (1Y): 0.05
Revenue Growth: -19.04%
EPS Growth: -56.75%
Country: Mexico
Employees: 660
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

InMode Business Overview & Revenue Model

Company Description

InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical s...

InMode Earnings Call Summary

Earnings Call Date:May 05, 2026(Q1-2026)|% Change Since:4.55%|Next Earnings Date:Nov 10, 2026

Earnings Call SentimentNeutral

The call contained a mix of modest top-line progress and strategic positives (5% revenue growth, strong cash balance, product launches, sales reorganization and share repurchases) offset by notable margin compression, rising operating expenses and declines in EPS. Management provided steady full-year guidance and described early signs of stabilization in the U.S., but profitability pressures and macroeconomic headwinds temper the outlook. International and product development initiatives offer upside, while near-term margin and demand uncertainty are the primary negatives.

Positive Updates

Revenue Growth

Total revenue of $82.0M in Q1 2026, up 5% from $77.9M in Q1 2025, driven primarily by stronger U.S. performance.

Negative Updates

Gross Margin Compression

GAAP gross margin fell to 75% in Q1 2026 from 78% in Q1 2025; non-GAAP gross margin fell to 75% from 79% a year ago, with management warning new laser platforms may put additional pressure on gross margins.

Company Guidance

The company reiterated 2026 guidance calling for revenue of $365–$375 million, non‑GAAP gross margin of 74%–76%, non‑GAAP income from operations of $73–$78 million, and non‑GAAP diluted EPS of $1.33–$1.38; for context, Q1 results included $82.0 million revenue, 75% non‑GAAP gross margin, 17% non‑GAAP operating margin, $0.25 non‑GAAP diluted EPS and $15.4 million cash from operations, while the balance sheet held $537.2 million in cash/marketable securities and the company returned capital via $127.4 million repurchases in 2025 plus $52.7 million year‑to‑date in 2026 (3.86 million shares).

InMode Risk Analysis

InMode disclosed 61 risk factors in its most recent earnings report. InMode reported the most risks in the "Production" category.

Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

1 New Risk

1.We have limited business in Russia which pose some degree of sanctions risk that cannot be entirely eliminated.Q4, 2022

InMode Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:INMDN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CNMD	67Neutral	$1.32B	18.30	7.07%	―	1.93%	16.93%
RCEL	54Neutral	$484.01M	-10.79	231.87%	―	1.00%	26.76%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ESTA	51Neutral	$1.86B	-48.86	-203.65%	―	38.25%	55.14%
IART	47Neutral	$991.96M	75.98	1.24%	―	0.84%	―
SRTS	46Neutral	$45.44M	-2.94	-34.09%	―	-53.40%	-1719.88%

* Healthcare Sector Average

Performance Comparison

MX:INMDN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:INMDN	Inmode	251.20	10.94	4.55%
CNMD	Conmed Corporation	46.59	0.88	1.93%
IART	Integra Lifesciences	13.61	2.31	20.44%
RCEL	Avita Medical Ltd	15.41	11.79	325.69%
SRTS	Sensus Healthcare, Inc.	2.75	-0.73	-20.98%
ESTA	Establishment Labs Holdings	61.07	11.67	23.62%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

InMode AI Stock Analysis